Drug Database
Back to search

Netherlands· NL-84ffecc8a303

Mayzent 2 mg, filmomhulde tabletten

A siponimod product containing siponimod fumaraat, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.

ATC L04AE03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMayzent 2 mg, filmomhulde tablettenATCL04AE03REGISTER NO.NL-84ffecc8a303PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about siponimod fumaraatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Siponimod is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AE03 (siponimod), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search siponimod products by name

Siponimod · ATC L04AE03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of siponimod costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Siponimod · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • IT Italy$120.54
  • CH Switzerland$118.82
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
SIPONIMOD FUMARAAT
Manufacturer
Novartis Europharm Limited
Country
Netherlands (NL)
ATC code
L04AE03
ATC class
Siponimod
Defined daily dose
2 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/19/1414

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

667 interactions on record for siponimod.

Graded by severity as the source publishes them — 597 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check siponimod against other medicinesHow interaction checks work

Siponimod · interactions on record

667 records

  • 597 severe
  • 66 moderate
  • 4 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • NizatidineA02BA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Siponimod in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All siponimod products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mayzent
  • Liechtenstein · Mayzent
  • Norway · Mayzent

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/600cc00e-c125-4ed5-90f6-7c2ad5d6eb7f
GET /v1/drugs/600cc00e-c125-4ed5-90f6-7c2ad5d6eb7f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Siponimod",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp123806",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "GLYCEROLDIBEHENAAT",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "LECITHINE, SOYA (E 322)",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "SIPONIMOD FUMARAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2020/01/13",
  "procedure_number": "EMEA/H/C/004712",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/19/1414",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about siponimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console